WeVote

Bill

Bill

LC 578

Revise unfair trade practices and consumer protections involving prescription drugs under the federal 340B program

2025 Regular Session

Montana bill to regulate unfair trade practices in 340B prescription drug program died in legislative process without advancing for formal consideration.

(LC) Draft Died in Process
0
WeVote Research Nonpartisan
Bill Summary · LC 578

Legislative bill overview

LC 578 proposes to revise Montana's unfair trade practices and consumer protection laws as they apply to prescription drugs distributed through the federal 340B program—a federal initiative that requires pharmaceutical manufacturers to offer discounted prices to certain healthcare facilities and organizations serving low-income populations. The bill died in the legislative process without advancing to a formal hearing or vote.

Why is this important

The 340B program significantly affects drug pricing and accessibility for vulnerable populations, including safety-net hospitals, federally qualified health centers, and AIDS service organizations. Any state-level modifications to how these drugs are regulated could impact both consumer access to affordable medications and the business practices of healthcare providers participating in the program.

Potential points of contention

  • Federal-state regulatory overlap: The 340B program is federally regulated; unclear whether Montana legislation could effectively modify practices without conflicting with federal authority
  • Stakeholder interests: Hospitals and nonprofits benefit from 340B discounts, while pharmaceutical manufacturers and some commercial competitors may oppose restrictions on their pricing practices
  • Implementation ambiguity: The bill's specific provisions are not detailed in available records, making it difficult to assess whether proposed protections would be workable or create unintended market distortions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.